Spironolactone Shortage: What Providers and Prescribers Need to Know in 2026

Spironolactone has been a clinical workhorse for over six decades. Prescribers across cardiology, nephrology, endocrinology, dermatology, and primary care rely on it for its unique combination of aldosterone antagonism and anti-androgenic activity. The supply disruptions affecting spironolactone in 2025-2026 — most notably the Pfizer Aldactone discontinuation — require providers to be proactive in patient counseling and prescribing strategy.

Current Supply Status (Early 2026)

As of early 2026, the FDA's Drug Shortage Database does not list a formal shortage of generic spironolactone tablets in the United States. However, two disruptions are clinically relevant:

Pfizer's permanent discontinuation of brand-name Aldactone 25 mg and 100 mg tablets removes a major brand reference standard from US supply chains.

Canada's 2025 shortage of both branded and generic spironolactone illustrated how quickly supply can destabilize when concentrated among a small number of API manufacturers.

Multiple generic manufacturers (including Zydus Pharmaceuticals and others) continue to supply the US market with 25 mg, 50 mg, and 100 mg generic spironolactone tablets. Localized pharmacy-level stock-outs are occurring, particularly for the 100 mg dose.

Prescribing Best Practices During Supply Disruption

Proactively adjusting prescribing practices can reduce patient-level access disruptions:

Prescribe generically: Avoid 'Aldactone' brand-name prescriptions. Write 'spironolactone' and do not mark DAW (Dispense As Written). Patients who present with Aldactone prescriptions may be turned away unnecessarily by pharmacy staff who haven't updated their system.

Discuss dose flexibility: For patients prescribed 100 mg, proactively note on the prescription whether two 50 mg tablets are an acceptable substitute if 100 mg is unavailable. This gives pharmacists flexibility to dispense what's in stock.

Favor 90-day supplies: For stable patients, a 90-day supply reduces the frequency of refill encounters and reduces exposure to temporary stock-outs. Encourage mail-order pharmacy.

Counsel patients proactively: Inform patients that Aldactone brand is no longer manufactured but generic spironolactone remains available. Provide them with the name of a backup pharmacy or tool (such as medfinder) to use if their usual pharmacy is out.

Therapeutic Substitution Guidance by Indication

When a patient truly cannot obtain spironolactone, the choice of alternative depends on clinical indication. No single agent replicates all of spironolactone's effects.

Heart Failure (HFrEF, NYHA Class III-IV)

Eplerenone (Inspra) is the evidence-based alternative for heart failure. It demonstrated mortality benefit in the EPHESUS trial (post-MI heart failure) and the EMPHASIS-HF trial (HFrEF). Dose equivalency: approximately 25 mg spironolactone ≈ 25-50 mg eplerenone (eplerenone is less potent milligram-for-milligram, requiring roughly 4x the dose for equivalent aldosterone blockade). Eplerenone is preferred in men due to absence of gynecomastia risk.

Clinical caveat: Eplerenone is more expensive and some payers require prior authorization or step therapy documentation. Document the shortage circumstance when submitting PA requests.

Hypertension (Resistant or Aldosterone-Mediated)

For resistant hypertension, eplerenone is the preferred substitute (25-50 mg daily). Amiloride 5-10 mg daily is a less potent but more affordable alternative that maintains potassium-sparing diuresis. Spironolactone has approximately 3.3x the antihypertensive potency of amiloride at equivalent doses. For patients with primary aldosteronism, eplerenone is strongly preferred over amiloride, as amiloride does not block aldosterone at the receptor level.

Edema (Cirrhosis, CHF, Nephrotic Syndrome)

For cirrhotic ascites, spironolactone is the preferred diuretic and is difficult to replace equivalently. Amiloride 5-10 mg can substitute when spironolactone causes intolerable side effects or is unavailable, though evidence is less robust. Loop diuretics (furosemide) may need dose adjustment when potassium-sparing agents are unavailable. Monitor electrolytes closely with any substitution in cirrhotic patients.

Acne Vulgaris and Hirsutism (Off-Label)

For acne vulgaris in adult women, combined oral contraceptives with androgen-receptor activity (Yaz/drospirenone+EE, Ortho Tri-Cyclen, Beyaz) provide FDA-approved alternatives. Short courses of tetracyclines (doxycycline 100 mg BID or minocycline) can bridge while access is restored. Clascoterone (Winlevi) 1% cream is a topical anti-androgen approved for acne that may be appropriate for patients who prefer to avoid systemic therapy.

For hirsutism, finasteride (off-label) and flutamide (off-label, with liver monitoring) are alternatives. These require careful risk-benefit assessment and informed consent.

Helping Patients Find Their Medication

When your patients report difficulty filling spironolactone, consider directing them to medfinder for providers. medfinder calls pharmacies on patients' behalf to identify which ones can fill their prescription, then texts them the results — dramatically reducing the time patients spend searching and reducing the likelihood they'll go without medication.

Monitoring Considerations During Substitution

Obtain baseline BMP (potassium, creatinine, BUN) within 1-2 weeks of switching agents in heart failure and CKD patients.

Blood pressure and weight monitoring within 4 weeks for patients switching MRA for hypertension or edema.

For patients with cirrhosis, closer monitoring of renal function and serum sodium is warranted when switching to amiloride.

For a practical guide on helping patients locate their medication, see our companion article: How to help your patients find spironolactone in stock: a provider's guide.